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Abstract
Tumours of ovarian-epithelial type of the testis, including serous borderline tumours, represent very rare entities.
They are identical to the surface epithelial tumours of the ovary and have been reported in patients from 14 to
68 years of age. We describe two cases of a 46- and a 39-year old man with incidental findings of intratesticular
masses of the left respectively right testis. Under the assumption of a malignant testicular tumour the patients were
subjected to inguinal orchiectomy. Histologically, the tumours were identical to their ovarian counterparts: They
showed a cystic configuration with a fibrous wall and irregular papillary structures lined by partially multistratified
columnar cells and areas of hobnail cells. Furthermore, there was mild cytological atypia with a proliferative activity
of below 5 % as proved by Ki67 staining; mitoses could not be detected. Immunohistochemically, the tumour cells
displayed expression of pan-cytokeratin AE3, progesterone receptor, Wilms’ tumour protein (WT1), and PAX8
(Paired box gene 8). Estrogen receptor was expressed in one case. Octamer-binding transcription factor-4 (OCT4),
calretinin, thrombomodulin, and D2-40 were not expressed. Mutation testing of BRAF revealed a BRAF V600E
mutation in one case, while testing for KRAS mutations proved to be negative in both. The BRAF mutated tumour
showed strong cytosolic and membranous positivity for B-Raf also on immunohistochemical analysis. Comparative
genomic hybridization of one case could not reveal any chromosomal aberrations.
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Background
Tumours of ovarian epithelial types of the testis repre-
sent rare entities, which histologically resemble their
ovarian counterparts [1–3]. They have been reported in
patients from 14 to 68 years of age and usually present
as a scrotal enlargement [4]. In this case report we de-
scribe two cases of serous borderline tumours of the
testis in a 46- and a 39-year old patient. We will illus-
trate the clinicopathologic characteristics and the results
of BRAF and KRAS mutation analysis. In addition we




A 46-year-old man presented in the urological clinic
with painless heaviness of the left testis. Urological ex-
aminations showed an intratesticular mass of approxi-
mately 2 cm in diameter. On ultrasonography this mass
proved to be cystic and solid. The tumour markers were
not increased. Under the assumption of a malignant tes-
ticular tumour an inguinal orchiectomy was performed.
The macroscopic inspection of the surgical specimen,
which consisted of testis and testicular appendages, pre-
sented a total weight of 23 g and a size of 5 × 4.5 × 3 cm.
The cut surface of the testis showed an intraparenchymal,
circumscribed formation of cystic appearance with a
diameter of 1.4 cm and whitish color.
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Case 2
A 39-year-old man showed an intratesticular mass of ap-
proximately 1.5 cm in diameter on urological examina-
tions. The tumour markers were not increased. Under the
assumption of a malignant testicular tumour an inguinal
orchiectomy was performed. The surgical specimen,
which consisted of testis and testicular appendages, pre-
sented a total weight of 30 g and a size of 6 × 4 × 3.5 cm.
The cut surface of the testis showed an intraparenchymal,
circumscribed tumour of cystic appearance with a diam-
eter of 2 cm.
Histology
Microscopic examination of testicular sections con-
firmed the cystic nature of the lesions, which were lined
by a fibrous capsule (Fig. 1a) and contained residues of
clear fluid. Intraluminal, irregular papillary structures
lined by partially multistratified columnar cells and areas
of hobnail cells could be seen. The tumour cells exhib-
ited eosinophilic cytoplasm, the nuclei showed predom-
inantly dense chromatin with prominent nucleoli
(Fig. 1b-f ). Furthermore, there was mild cytological aty-
pia but no mitoses (Fig. 1g + h). Psammoma bodies
could not be detected. Proliferative activity revealed by
Ki67 staining was below 5 % in both cases (Fig. 2a).
Immunohistochemical examination of the tumour cells
displayed expression of pan-cytokeratin AE3 (Fig. 2b),
estrogen- and progesterone receptor (Fig. 2c-d), Wilms’
tumor protein (WT1), and PAX8 (Paired box gene 8).
The BRAF mutated tumour showed strong cytosolic and
membranous positivity for B-Raf. Octamer-binding tran-
scription factor-4 (OCT4), calretinin, thrombomodulin
and D2-40 were not expressed. The histological findings
supported the diagnosis of a serous borderline tumour.
The tumour-free testicular tissue displayed regular tu-
bules with intact spermatogenesis and normal interstitial
tissue. A Fallopian tubal metaplasia in the paratesticular
epithelial structures or ovarian stroma could not be
detected. An overview of the immunohistochemical
analysis is listed in Table 1.
BRAF and KRAS mutation analysis
DNA was isolated from the formalin-fixed and paraffin
embeded tumour tissue with InnuPure-Kit and the Innu-
Pure C16 according to the manufacturer’s protocol
(Analytik Jena, Jena, Germany). Mutation analyses of
both samples were carried out with pyro-sequencing
using the Pyromark Q24 (QIAGEN, Hilden, Germany).
For KRAS analysis the therascreen KRAS Pyro Kit CE
24 T and therascreen RAS extension Pyro Kit (both
QIAGEN) were used. For BRAF analysis the therascreen
BRAF Pyro Kit (QUIAGEN) was used. Sequencing was
performed according to manufacturer’s protocol. Mutation
analysis of BRAF revealed a BRAF V600E (c.1799 T >A)
mutation in one case. BRAF codon 464–469 revealed
a wild type. Testing for KRAS mutations in exon 2–4
proved to be of wild type in both tumours (Fig. 2e).
The clinicopathologic data and cytogenetic findings
are listed in Table 2.
Comparative genomic hybridization (CGH)
CGH was performed as described previously [5]. Com-
parative genomic hybridization, which was carried out in
only one of the tumours due to a lack of tissue, could
not detect any chromosomal aberrations.
Discussion
The similarities of male and female germ cell tumours
are well known and have been described numerous
times in the medical literature. Conversely, there is
little information about the much rarer tumours of
ovarian epithelial type of the testis and paratesticular
tissue. The most commonly observed among these
are serous tumours with the majority being of border-
line malignancy [6–8, 2, 1, 9]. Invasive carcinoma has
to be excluded by the presence of accentuated cellular
atypia, necrosis, and stromal invasion. Therefore, ex-
tensive sampling of all cases of borderline tumour
should be carried out.
It is still a matter of discussion, whether ovarian-type
epithelial tumours of the testis originate from the rem-
nants of Müllerian ducts in paratesticular connective
tissue, epididymis, and spermatic cord or from Müllerian
metaplasia of the mesothelium of the tunica vaginalis
testis. The latter theory is supported by the frequent
finding of metaplastic serous Müllerian epithelium in
these tumours [10]. Likewise, a Müllerian metaplasia of
intratesticular mesothelial inclusions, possibly triggered
by injury during embryogenesis, is also imaginable [11].
One of the key questions in the diagnosis of ovarian-
type epithelial tumours is their distinction from clinically
aggressive neoplasms such as mesothelioma of the tu-
nica vaginalis testis and carcinoma of the rete testis. Be-
sides histological features of mesothelioma such as a low
cellularity and the absence of psammoma bodies, immu-
nohistochemical mesothelial markers such as D2-40,
thrombomodulin, and calretinin can prove to be helpful
for this purpose. Serous tumours, for the most part,
show an opposite immunohistochemical pattern for
those antigens and express ovarian epithelial tumour
markers such as epithelial membrane antigen (EMA), CA-
125 (cancer antigen 125), cytokeratin 7, CD15 (Leu-1),
and Ber-EP4. The immunohistochemical expression of
PAX8 (Paired box gene 8) in ovarian-type epithelial tu-
mours is also a very valuable tool for the distinction as it
is only rarely traceable in malignant mesothelioma [12].
Wilms’ tumor protein (WT1) is regularly expressed not
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only in malignant mesotheliomas but also in ovarian
serous carcinomas and thus is not suitable to distinguish
these tumour entities. Rare differential diagnoses comprise
local spread of adenocarcinoma of the rete testis and
adenocarcinoma of the epididymis. Typical histological
features of serous borderline tumours that were also
present in our cases are their cystic nature and papillary
budding, which led to the exclusion of adenocarcinoma of
the rete testis and epididymis. Furthermore, no foci of
stromal invasion could be detected.
Several authors have shown chromosomal aberrations,







Fig. 1 Serous borderline tumour of the testis: Ultrasound examination shows an unilocular cyst with intracystic papillae (a). Histologically, the
tumour shows papillary structures encased by a fibrous wall with cystic areas filled with clear fluid (b; x20). The tumour cells present with mild
cytologic atypia and eosinophilic cytoplasm, the nuclei show a predominantly dense chromatin with prominent nucleoli (c; x40 and d; x100; e,
x200; f, x200; g, x400; h, x600)
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2q, 6q, 5, 8q and 12 and losses of 1p, 17p, 19 and 22q
[13–18] in sets of borderline tumours of the ovary
using comparative genomic hybridization (CGH). How-
ever, only half of the analyzed cases showed any
chromosomal changes at all. CGH of one of the testicu-
lar borderline tumours was not able to detect any
aberrations, which is in concordance with the studies
on ovarian specimen and the overall low-grade nature
of the lesion.
The BRAF-protooncogene is a downstream mediator
of KRAS and the substitution of valine (V) to glutamic
acid (E) at the position 600 of the amino acid sequence
causes its most common activating mutation (T1799A).






Fig. 2 Serous borderline tumour of the testis: The Ki67 staining exhibits low proliferative activity (a; ×100); Lining Epithelial tumour cells express
pan-Cytokeratin AE3 (b; x200), estrogen receptor (c; x400), progesterone receptor (d; x400), and PAX8 (e; x100). The tumour with BRAF mutation
shows immunohistochemical B-Raf positivity (f, x400). Mutatation analysis revealed a BRAF V600E (c.1799 T > A) mutation in one case (g)
Table 1 Immunohistochemical analyses
CK ER PR PX8 WT1 TM CAL D2 OCT Ki Br
Case 1 + 60 % 40 % + + - - - - <5 % +
Case 2 + - 5 % + + - - - - <5 % -
CK cytokeratin, ER estrogenreceptor, PR progesteronreceptor, PX8 PAX8, WT1
Wilms’ tumor protein, TM thrombomodulin, CAL calretinin, D2 podoplanin, OCT
OCT4, Ki Ki67, Br serine/threonine-protein kinase B-Raf
Table 2 Clinicopathologic data and cytogenetic findings
Age Chromosomal alterations (CGH) BRAF V600E KRAS
Case 1 46 none c.1799 T > A WT
Case 2 39 none WT WT
CGH comparative genomic hybridization, WT wild type
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V600E and its detection by mutation analysis and immu-
nohistochemistry in both serous borderline tumours and
low-grade invasive carcinoma of the ovary [19, 20]. Mu-
tations in either BRAF or KRAS can frequently be seen in
low grade serous adenocarcinoma and borderline tumours
of the ovary and seem to be mutually exclusive [21]. How-
ever, high-grade carcinomas usually feature a different
genetic profile with mutations of TP53 and NRAS [22].
To our knowledge only one very recent study has shown a
mutation of BRAF V600E in a serous borderline tumour
of the testis [23]. This, together with our findings, supports
a common pathogenesis in serous borderline tumours of
both female and male.
Conclusions
Ovarian-type epithelial tumours of the testis are ex-
tremely rare and not well studied tumour entities. The
detection of a BRAF-mutation, which is common in
ovarian serous borderline tumours, points to a common
pathogenesis of these entities in both genders. Because
the differential diagnosis of these tumours includes malig-
nant entities such as mesothelioma and carcinoma of the
rete testis, the correct diagnosis, possibly aided by genetic
markers, is important for the optimal management.
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